Analysis of:
Lilly to Disclose Payments to Doctors (online.wsj.com)
It will become public knowledge what Doctors are paid by Lilly for advice, lectures and other services.
Analysis of:
Shorter Radiation for Cancer of the Breast (www.nytimes.com)
Results are identicle (3 weeks v 5 in post lumpectomy radiation?)
Analysis of:
Stark Offers Bill to Hasten e-record Adoption (modernhealthcare.com)
Adoption of mandatory computerization will be gently forced on physicians and their offices
Analysis of:
Raising the Profile of Cancer of Unknown Primary (jco.ascopubs.org)
RNA gene profiling will allow up to get a better handle on the primary site, especially with increasing targeting opportunities in many neoplasms.
Analysis of:
Proton Radiotherapy: A Review (www.nytimes.com)
Proton beam therapy will effect the market place and force competition for oncology centers to get "the next best thing."
Analysis of:
Velcade (Black Triangle Drug) (bortezomib) Approved For Previously Untreated Multiple Myeloma (www.therapeuticsdaily.com)
Velcade, given with Melphalan & Prednisone approved for use 1st line in non-transplant myeloma patients first line.
Analysis of:
Gefitinib Versus Vinorelbine in Chemotherapy-Naïve Elderly Patients With Advanced Non–Small-Cell Lung Cancer (INVITE): A Randomized, Phase II Study (jco.ascopubs.org)
2 separate studies show that: 1. "...there was no statistically significant difference in overall survival....for gefitinib compared with docetaxel. Gefitinib remains an effective treatment option for previously treated Japanese patients with NSCLC." http://jco.ascopubs.org/cgi/content/full/26/26/4244...
Analysis of:
In Long-Awaited Maps of Cancer, The Breakthrough Is the Problem (online.wsj.com)
Pharmacogenomics will lead to the development of targeting agents and offer true hope for the future.
Analysis of:
Gleevec Receives FDA Priority Review as First Therapy to Reduce Recurrence of Gastrointestinal Stromal Tumors After Surgery (www.therapeuticsdaily.com)
Novartis is looking for approval for therapy in C-KIT + Gastrointestinal stromal tumors
Analysis of:
Expanding Circle of Inhibition: Small-Molecule Inhibitors of Bcl-2 as Anticancer Cell and Antiangiogenic Agents (jco.ascopubs.org)
Bcl-2 inhibition by small molecules stands to be the next avenue for antineoplastic therapy- Looks like the real deal!